
Medics struggle to revive Sudan's hungry with trickle of aid supplies
The patients at Alban Jadeed Hospital are in urgent need of help after nearly two years of battles that have trapped residents and cut off supplies, but doctors have to ration the therapeutic milk and other products used to treat them.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
The war that erupted in April 2023 from a power struggle between Sudan's army and the paramilitary Rapid Support Forces (RSF) has created what the United Nations calls the world's largest and most devastating humanitarian crisis.
About half of Sudan's population of 50 million now suffer some degree of acute hunger, and famine has taken hold in at least five areas, including several parts of North Darfur State in western Sudan.
The real situation could be worse, since fighting has prevented proper data collection in many areas, medics and aid staff say.
In Sudan's greater capital, where the cities of Khartoum, Omdurman and Bahri are divided by the Nile, the warring factions have prevented deliveries of aid and commercial supplies, pushing the prices of goods beyond most people's reach.
Alban Jadeed Hospital, in Bahri's Sharg Elnil district, received more than 14,000 children under five years old suffering from severe acute malnutrition last year, and another 12,000 with a more mild form, said Azza Babiker, head of the therapeutic nutrition department.
Only 600 of the children tested were a normal weight, she said.
The supply of therapeutic formula milk via U.N. children's agency UNICEF and medical aid agency MSF is insufficient, Babiker said, as RSF soldiers twice stole the supplies.
Both sides deny impeding aid deliveries.
The sharp reduction of USAID funding is expected to make things worse, hitting the budgets of aid agencies that provide crucial nutritional supplies as well as community kitchens relied upon by many, aid workers say.
The army recently captured Sharg Elnil from the RSF, as part of recent gains it has made across the capital.
Fruit and vegetables have become extremely scarce. "Aside from the difficulty of getting these products in, not all families can afford to buy them," Babiker said.
Many mothers are unable to produce milk, often due to trauma resulting from RSF attacks, or their own malnutrition, said Raneen Adel, a doctor at Alban Jadeed.
"There are cases who come in dehydrated ... because for example the RSF entered the house and the mother was frightened so she stopped producing breast milk, or she was beaten," she said.
The RSF did not immediately respond to a request for comment.
A lack of nutrition and sanitation has led to cases of blood poisoning and other illnesses, but the hospital has also run out of antibiotics.
"We had to tell the patients' companions to get (the drugs) from outside, but they can't afford to buy them," Adel said.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
12 hours ago
- Reuters
UK agrees deal with Vietnam to remove pharmaceutical trade barriers
LONDON, July 14 (Reuters) - Britain said it would strike an agreement with Vietnam to make it easier for pharmaceutical firms to sell UK-made medicines in the Southeast Asian nation, under a new trade strategy that emphasises quick, industry-specific deals. Britain launched the new strategy last month, promising a nimbler approach compared to the emphasis it placed on full-fledged free trade agreements following its departure from the European Union. Vietnam will hasten the registration of new medicines and vaccines, while recognising approvals from more regulators, including Britain's Medicines and Healthcare products Regulatory Agency, the British government told Reuters in a statement. The deal is expected to be confirmed later on Monday. "The removal of pharmaceutical barriers with one of our closest trading partners in Asia is a boost for the UK pharmaceutical industry and proof our Industrial and Trade Strategies are already delivering," British trade minister Douglas Alexander said. The deal could be worth 250 million pounds ($337 million) to the British pharmaceutical sector over the next five years, the government added. The UK-Vietnamese Joint Economic and Trade Committee will meet in London on Monday and also discuss financial services and renewable energy. Britain has taken a tougher line on some other sectors, however, with steel imports from Vietnam set to be restricted under a new quota regime. Life sciences, including pharmaceuticals, are a priority sector under Britain's new industrial strategy, which was also launched last month. However, that plan has been delayed by a dispute over drug pricing with the British pharmaceutical sector, which says the government needs to value medicines more fairly and adjust the payments they make back to the health service. ($1 = 0.7415 pounds)


Reuters
3 days ago
- Reuters
Drowning deaths in France spiked by 58% during heat wave, authorities say
PARIS, July 11 (Reuters) - France's public health authority said on Friday that more than 100 people had died from drowning between June 1 and July 2 this year, an increase of 58% over the same period last year, blaming it on unusually warm weather at the end of June. Sante Publique, the French authority, said 429 total drownings had occurred in France between June 1 and July 2, an increase of 95% over that period last year. "These increases occurred in a context of high temperatures in the second half of June 2025, which led to an increase in people going to swimming areas to cool off," the agency said in a bulletin. Large swaths of Europe, including France, sweltered over a 10-day heatwave ending July 2. Scientists said 2,300 people died of heat-related causes across 12 European cities during the extreme weather.


Reuters
6 days ago
- Reuters
Judge orders CVS' Omnicare unit to pay $949 million over invalid prescriptions
NEW YORK, July 8 (Reuters) - A federal judge ordered CVS Health's (CVS.N), opens new tab Omnicare unit to pay $948.8 million in penalties and damages, in a whistleblower lawsuit claiming it fraudulently billed the U.S. government for invalid drug prescriptions. In a Monday evening order, U.S. District Judge Colleen McMahon in Manhattan imposed a $542-million penalty for filing 3,342,032 false claims between 2010 and 2018. McMahon also awarded $406.8 million of damages, representing three times the $135.6 million that a jury awarded on April 29. The tripling was required under the federal False Claims Act, which lets whistleblowers sue on behalf of the federal government and share in recoveries. CVS plans to appeal the judgment. The Woonsocket, Rhode Island-based drugstore chain and pharmacy benefits manager bought Omnicare in 2015. Omnicare has asked McMahon to throw out the case or grant a new trial. "This lawsuit centered on a highly technical prescription dispensing recordkeeping issue that was allowed by law in many states," CVS said in a statement on Tuesday. "There was no claim in this case that any patient paid for a medication they shouldn't have or that any patient was harmed." The lawsuit was filed in 2015 by Uri Bassan, a former Omnicare pharmacist in Albuquerque, New Mexico, and joined by the federal government in 2019. They said Omnicare improperly billed Medicare, Medicaid, and Tricare, which serves military personnel, for prescriptions for tens of thousands of patients in assisted-living facilities, group homes for people with special needs, and other long-term care facilities. Omnicare allegedly assigned new prescription numbers without necessary paperwork and pharmacist approvals, after the original prescriptions expired or ran out of refills. McMahon rejected CVS' argument that a $948.8-million award violated the U.S. Constitution's prohibition against excessive fines under the Eighth Amendment. "This was a very big fraud on the government, one that lasted over almost a decade, and one that Omnicare was aware of but avoided taking steps to correct," the judge wrote. McMahon found CVS jointly liable with Omnicare for $164.8 million of the penalties, after jurors found it failed to stop Omnicare from submitting 30% of the false claims after buying that company. CVS itself did not submit any claims. The case is U.S. ex rel Bassan v. Omnicare Inc, U.S. District Court, Southern District of New York, No. 15-04179.